Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-03-22
2011-03-22
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100, C424S130100, C424S133100, C424S144100
Reexamination Certificate
active
07910708
ABSTRACT:
The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
REFERENCES:
patent: 6468528 (2002-10-01), Mak et al.
patent: 7282206 (2007-10-01), Wynn et al.
patent: 2003/0143199 (2003-07-01), Carson et al.
patent: 2004/0023337 (2004-02-01), Heavner et al.
patent: 2004/0028650 (2004-02-01), Van Snick et al.
patent: 2004/0242841 (2004-12-01), Cammack et al.
patent: 2004/0248260 (2004-12-01), Heavner et al.
patent: 2005/0054055 (2005-03-01), Kucherlapati et al.
patent: 2005/0065327 (2005-03-01), Monk et al.
patent: 2005/0096268 (2005-05-01), Wynn et al.
patent: 2006/0063228 (2006-03-01), Kasaian et al.
patent: 2006/0073148 (2006-04-01), Tchistiakova et al.
patent: 2008/0044420 (2008-02-01), Heavner et al.
patent: 2009/0297524 (2009-12-01), Grant et al.
patent: 2403952 (2005-01-01), None
patent: WO 94/04680 (1994-03-01), None
patent: WO 00/36103 (2000-06-01), None
patent: WO 00/56771 (2000-09-01), None
patent: WO 01/62933 (2001-08-01), None
patent: WO 03/007685 (2003-01-01), None
patent: WO 03/034984 (2003-05-01), None
patent: WO 03/086451 (2003-10-01), None
patent: WO 03/092610 (2003-11-01), None
patent: WO 03/102157 (2003-12-01), None
patent: 2004/050850 (2004-06-01), None
patent: 2005/007699 (2005-01-01), None
patent: WO 2005/062967 (2005-07-01), None
patent: 2005/091853 (2005-10-01), None
patent: WO 2005/121177 (2005-12-01), None
patent: WO 2006/003407 (2006-01-01), None
patent: 2006/055638 (2006-05-01), None
patent: WO 2006/085938 (2006-08-01), None
patent: 2006/124451 (2006-11-01), None
patent: WO 2007/036745 (2007-04-01), None
patent: WO 2007/041219 (2007-04-01), None
patent: 2007076062 (2007-07-01), None
patent: WO 2007/076062 (2007-07-01), None
patent: WO 2007/080174 (2007-07-01), None
patent: WO 2007/085815 (2007-08-01), None
Rudikoff, Giusti, Cook, and Scharff. Single amino acid substitution altering antigen-binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
Mac Callum, Martin, and Thornton. Antibody- antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of abbreviated complementarity determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Chen, Wiesmann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen binding site of an Anti-ErbB2 antibody obtained by shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320. pp. 415-428.
Blanchard et al., “Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354)”, Clinical and Experimental Allergy, 2005 vol. 35, No. 8, pp. 1096-1103.
Yang et al., “Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling”, Cytokine, 2004 vol. 28 No. 6 pp. 224-232.
Kumar et al., “Effects of Anticytokine Therapy in a Mosue model of Chronic Asthma,” Am J Resp Crit Care Med 170 (10):1043-1048 (2004).
Buechler Joe
Campbell Emma
Parveen Sofia
Valkirs Gunars
Gussow Anne M.
Lacourse Karen A.
Novartis AG
LandOfFree
Anti-IL13 human antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-IL13 human antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IL13 human antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2747480